Attenuated oncolytic measles virus strains as cancer therapeutics

Current Pharmaceutical Biotechnology

Volumn 13, Issue 9, 2012, Pages 1732-1741

  Msaouel, P ^a   Iankov, I D ^a   Dispenzieri, A ^a   Galanis, E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer gene therapy; Cell carriers; Combination therapy; Oncolytic measles; Tumor targeting; Virotherapy

Indexed keywords

ATTENUATED ONCOLYTIC MEASLES VIRUS CEA; ATTENUATED ONCOLYTIC MEASLES VIRUS EDMONSTON ZAGREB STRAIN; ATTENUATED ONCOLYTIC MEASLES VIRUS EGFP PWT; ATTENUATED ONCOLYTIC MEASLES VIRUS NIS; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; GLIOBLASTOMA; HUMAN; MEASLES VIRUS; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; REVIEW; SUBCUTANEOUS T CELL LYMPHOMA; TREATMENT OUTCOME; VIROTHERAPY; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MEASLES VACCINE; MEASLES VIRUS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VACCINES, ATTENUATED;

MEASLES VIRUS;

EID: 84863543763     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800958896     Document Type: Review

References (103)

1. Liu, T. C.; Galanis, E.; Kirn, D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol., 2007, 4 (2), 101-117.
2. Msaouel, P.; Dispenzieri, A.; Galanis, E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr. Opin. Mol. Ther., 2009, 11 (1), 43-53.
3. Griffin, D. E.; Pan, C. H. Measles: old vaccines, new vaccines. Curr. Top. Microbiol. Immunol., 2009, 330, 191-212.
4. Hernandez, S. A. Observacion de un caso de enfermedad de Hodgkin, con regresion de los sintomas e infartos ganglionares, postsarampion. Arch. Cubanos. Cancer, 1949, 8, 26-31.
5. Bluming, A. Z.; Ziegler, J. L. Regression of Burkitt's lymphoma in association with measles infection. Lancet, 1971, 2 (7715), 105-106.
6. Gross, S. Measles and leukaemia. Lancet, 1971, 1 (7695), 397-398.
7. Mota, H. C. Infantile Hodgkin's disease: remission after measles. Br. Med. J., 1973, 2 (5863), 421.
8. Pasquinucci, G. Possible effect of measles on leukaemia. Lancet, 1971, 1 (7690), 136.
9. Zygiert, Z. Hodgkin's disease: remissions after measles. Lancet, 1971, 1 (7699), 593.
10. Taqi, A. M.; Abdurrahman, M. B.; Yakubu, A. M.; Fleming, A. F. Regression of Hodgkin's disease after measles. Lancet, 1981, 1 (8229), 1112.
11. Ziegler, J. L. Spontaneous remission in Burkitt's lymphoma. Natl. Cancer Inst. Monogr., 1976, 44, 61-65.
12. Yanagi, Y.; Takeda, M.; Ohno, S. Measles virus: cellular receptors, tropism and pathogenesis. J. Gen. Virol., 2006, 87 (Pt 10), 2767-2779.
13. Wild, T. F.; Malvoisin, E.; Buckland, R. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J. Gen. Virol., 1991, 72 (Pt 2), 439-442.
14. Phuong, L. K.; Allen, C.; Peng, K. W.; Giannini, C.; Greiner, S.; TenEyck, C. J.; Mishra, P. K.; Macura, S. I.; Russell, S. J.; Galanis, E. C. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res., 2003, 63 (10), 2462-2469.
15. Dingli, D.; Peng, K. W.; Harvey, M. E.; Greipp, P. R.; O'Connor, M. K.; Cattaneo, R.; Morris, J. C.; Russell, S. J. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood, 2004, 103 (5), 1641-1646.
16. Peng, K. W.; Ahmann, G. J.; Pham, L.; Greipp, P. R.; Cattaneo, R.; Russell, S. J. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood, 2001, 98 (7), 2002-2007.
17. Peng, K. W.; Facteau, S.; Wegman, T.; O'Kane, D.; Russell, S. J. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med., 2002, 8 (5), 527-531.
18. Galanis, E.; Bateman, A.; Johnson, K.; Diaz, R. M.; James, C. D.; Vile, R.; Russell, S. J. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum. Gene. Ther., 2001, 12 (7), 811-821.
19. Dhiman, N.; Jacobson, R. M.; Poland, G. A. Measles virus receptors: SLAM and CD46. Rev. Med. Virol., 2004, 14 (4), 217-229.
20. Jurianz, K.; Ziegler, S.; Garcia-Schuler, H.; Kraus, S.; Bohana- Kashtan, O.; Fishelson, Z.; Kirschfink, M. Complement resistance of tumor cells: basal and induced mechanisms. Mol. Immunol., 1999, 36 (13-14), 929-939.
21. Fishelson, Z.; Donin, N.; Zell, S.; Schultz, S.; Kirschfink, M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol., 2003, 40 (2-4), 109-123.
22. Ono, N.; Tatsuo, H.; Hidaka, Y.; Aoki, T.; Minagawa, H.; Yanagi, Y. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J. Virol., 2001, 75 (9), 4399-4401.
23. Schneider, U.; von Messling, V.; Devaux, P.; Cattaneo, R. Efficiency of measles virus entry and dissemination through different receptors. J. Virol., 2002, 76 (15), 7460-7467.
24. Vongpunsawad, S.; Oezgun, N.; Braun, W.; Cattaneo, R. Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J. Virol., 2004, 78 (1), 302-313.
25. Anderson, B. D.; Nakamura, T.; Russell, S. J.; Peng, K. W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res., 2004, 64 (14), 4919-4926.
26. Peng, K. W.; Donovan, K. A.; Schneider, U.; Cattaneo, R.; Lust, J. A.; Russell, S. J. Oncolytic measles viruses displaying a singlechain antibody against CD38, a myeloma cell marker. Blood, 2003, 101 (7), 2557-2562.
27. Blechacz, B.; Splinter, P. L.; Greiner, S.; Myers, R.; Peng, K. W.; Federspiel, M. J.; Russell, S. J.; LaRusso, N. F. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology, 2006, 44 (6), 1465-1477.
28. Liu, C.; Erlichman, C.; McDonald, C. J.; Ingle, J. N.; Zollman, P.; Iankov, I.; Russell, S. J.; Galanis, E. Heat shock protein inhibitors increase the efficacy of measles virotherapy. Gene Ther., 2008, 15 (14), 1024-1034.
29. Russell, S. J.; Peng, K. W. Measles virus for cancer therapy. Curr. Top. Microbiol. Immunol., 2009, 330, 213-241.
30. Ong, H. T.; Timm, M. M.; Greipp, P. R.; Witzig, T. E.; Dispenzieri, A.; Russell, S. J.; Peng, K. W. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp. Hematol., 2006, 34 (6), 713-720.
31. Naik, S.; Russell, S. J. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin. Biol. Ther., 2009, 9 (9), 1163-1176.
32. McQuillan, G. M.; Kruszon-Moran, D.; Hyde, T. B.; Forghani, B.; Bellini, W.; Dayan, G. H. Seroprevalence of measles antibody in the US population, 1999-2004. J. Infect. Dis., 2007, 196 (10), 1459-1464.
33. Radecke, F.; Spielhofer, P.; Schneider, H.; Kaelin, K.; Huber, M.; Dotsch, C.; Christiansen, G.; Billeter, M. A. Rescue of measles viruses from cloned DNA. EMBO. J., 1995, 14 (23), 5773-5784.
34. Blechacz, B.; Russell, S. J. Measles virus as an oncolytic vector platform. Curr. Gene. Ther., 2008, 8 (3), 162-175.
35. Billeter, M. A.; Naim, H. Y.; Udem, S. A. Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr. Top. Microbiol. Immunol., 2009, 329, 129-162.
36. Nakamura, T.; Peng, K. W.; Harvey, M.; Greiner, S.; Lorimer, I. A.; James, C. D.; Russell, S. J. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol., 2005, 23 (2), 209-214.
37. Hadac, E. M.; Peng, K. W.; Nakamura, T.; Russell, S. J. Reengineering paramyxovirus tropism. Virology, 2004, 329 (2), 217-225.
38. Grote, D.; Russell, S. J.; Cornu, T. I.; Cattaneo, R.; Vile, R.; Poland, G. A.; Fielding, A. K. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood, 2001, 97 (12), 3746-3754.
39. Bucheit, A. D.; Kumar, S.; Grote, D. M.; Lin, Y.; von Messling, V.; Cattaneo, R. B.; Fielding, A. K. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol. Ther., 2003, 7 (1), 62-72.
40. Ungerechts, G.; Springfeld, C.; Frenzke, M. E.; Lampe, J.; Johnston, P. B.; Parker, W. B.; Sorscher, E. J.; Cattaneo, R. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res., 2007, 67 (22), 10939-10947.
41. Hallak, L. K.; Merchan, J. R.; Storgard, C. M.; Loftus, J. C.; Russell, S. J. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res., 2005, 65 (12), 5292-5300.
42. Myers, R. M.; Greiner, S. M.; Harvey, M. E.; Griesmann, G.; Kuffel, M. J.; Buhrow, S. A.; Reid, J. M.; Federspiel, M. J.; Ames, M. M.; Dingli, D.; Schweikart, K.; Welch, A.; Dispenzieri, A.; Peng, K. W.; Russell, S. J. Preclinical pharmacology and toxicology of intravenous MVNIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin. Pharmacol. Ther., 2007, 82 (6), 700-710.
43. Hasegawa, K.; Hu, C.; Nakamura, T.; Marks, J. D.; Russell, S. J.; Peng, K. W. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J. Virol., 2007, 81 (23), 13149-13157.
44. Hasegawa, K.; Pham, L.; O'Connor, M. K.; Federspiel, M. J.; Russell, S. J.; Peng, K. W. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin. Cancer Res., 2006, 12 (6), 1868-1875.
45. Hasegawa, K.; Nakamura, T.; Harvey, M.; Ikeda, Y.; Oberg, A.; Figini, M.; Canevari, S.; Hartmann, L. C.; Peng, K. W. The use of a tropismmodified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin. Cancer Res., 2006, 12 (20 Pt 1), 6170-6178.
46. Peng, K. W.; TenEyck, C. J.; Galanis, E.; Kalli, K. R.; Hartmann, L. C.; Russell, S. J. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res., 2002, 62 (16), 4656-4662.
47. Allen, C.; Vongpunsawad, S.; Nakamura, T.; James, C. D.; Schroeder, M.; Cattaneo, R.; Giannini, C.; Krempski, J.; Peng, K. W.; Goble, J. M.; Uhm, J. H.; Russell, S. J.; Galanis, E. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res., 2006, 66 (24), 11840-11850.
48. Paraskevakou, G.; Allen, C.; Nakamura, T.; Zollman, P.; James, C. D.; Peng, K. W.; Schroeder, M.; Russell, S. J.; Galanis, E. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol. Ther., 2007, 15 (4), 677-686.
49. Liu, C.; Sarkaria, J. N.; Petell, C. A.; Paraskevakou, G.; Zollman, P. J.; Schroeder, M.; Carlson, B.; Decker, P. A.; Wu, W.; James, C. D.; Russell, S. J.; Galanis, E. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin. Cancer Res., 2007, 13 (23), 7155-7165.
50. Allen, C.; Paraskevakou, G.; Iankov, I.; Giannini, C.; Schroeder, M.; Sarkaria, J.; Puri, R. K.; Russell, S. J.; Galanis, E. Interleukin- 13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol. Ther., 2008, 16 (9), 1556-1564.
51. Allen, C.; Msaouel, P.; Aderca, I.; Penheiter, A. R.; Iankov, I.; Federspiel, M. J.; Opyrchal, M.; Carlson, S. K.; Russell, S. J.; Galanis, E. Optimizing the Antitumor Activity of Engineered Measles Virus Strains in the Treatment of Gliomas. Mol. Ther., 2009, 17 (Suppl 1), S108.
52. Kunzi, V.; Oberholzer, P. A.; Heinzerling, L.; Dummer, R.; Naim, H. Y. Recombinant measles virus induces cytolysis of cutaneous Tcell lymphoma in vitro and in vivo. J. Invest. Dermatol., 2006, 126 (11), 2525-2532.
53. Iankov, I. D.; Msaouel, P.; Allen, C.; Federspiel, M. J.; Bulur, P. A.; Dietz, A. B.; Gastineau, D.; Ikeda, Y.; Ingle, J. N.; Russell, S. J.; Galanis, E. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast. Cancer Res. Treat., 2009, 122(3),745-754
54. McDonald, C. J.; Erlichman, C.; Ingle, J. N.; Rosales, G. A.; Allen, C.; Greiner, S. M.; Harvey, M. E.; Zollman, P. J.; Russell, S. J.; Galanis, E. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res. Treat., 2006, 99 (2), 177-184.
55. Jing, Y.; Tong, C.; Zhang, J.; Nakamura, T.; Iankov, I.; Russell, S. J.; Merchan, J. R. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res., 2009, 69 (4), 1459-1468.
56. Iankov, I. D.; Blechacz, B.; Liu, C.; Schmeckpeper, J. D.; Tarara, J. E.; Federspiel, M. J.; Caplice, N.; Russell, S. J. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol. Ther., 2007, 15 (1), 114-122.
57. Zimmermann, M.; Armeanu, S.; Smirnow, I.; Kupka, S.; Wagner, S.; Wehrmann, M.; Rots, M. G.; Groothuis, G. M.; Weiss, T. S.; Konigsrainer, A.; Gregor, M.; Bitzer, M.; Lauer, U. M. Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses. Int. J. Oncol., 2009, 34 (5), 1247-1256.
58. Ungerechts, G.; Springfeld, C.; Frenzke, M. E.; Lampe, J.; Parker, W. B.; Sorscher, E. J.; Cattaneo, R. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol. Ther., 2007, 15 (11), 1991-1997.
59. Msaouel, P.; Iankov, I. D.; Allen, C.; Morris, J. C.; von Messling, V.; Cattaneo, R.; Koutsilieris, M.; Russell, S. J.; Galanis, E. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate, 2009, 69 (1), 82-91.
60. Liu, C.; Hasegawa, K.; Russell, S. J.; Sadelain, M.; Peng, K. W. Prostate- specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate, 2009, 69 (10), 1128-1141.
61. Msaouel, P.; Iankov, I. D.; Allen, C.; Aderca, I.; Federspiel, M. J.; Tindall, D. J.; Morris, J. C.; Koutsilieris, M.; Russell, S. J.; Galanis, E. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol. Ther., 2009, 17 (12), 2041-2048.
62. Carlson, S. K.; Classic, K. L.; Hadac, E. M.; Bender, C. E.; Kemp, B. J.; Lowe, V. J.; Hoskin, T. L.; Russell, S. J. In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol. Imaging. Biol., 2006, 8 (6), 324-332.
63. Carlson, S. K.; Classic, K. L.; Hadac, E. M.; Dingli, D.; Bender, C. E.; Kemp, B. J.; Russell, S. J. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am. J. Roentgenol., 2009, 192 (1), 279-287.
64. Gauvrit, A.; Brandler, S.; Sapede-Peroz, C.; Boisgerault, N.; Tangy, F.; Gregoire, M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumorspecific CD8 response. Cancer Res., 2008, 68 (12), 4882-4892.
65. Li, H.; Peng, K. W.; Dingli, D.; Kratzke, R. A.; Russell, S. J. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene. Ther., 2010, 17(8),550-558
66. Springfeld, C.; von Messling, V.; Frenzke, M.; Ungerechts, G.; Buchholz, C. J.; Cattaneo, R. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res., 2006, 66 (15), 7694-7700.
67. Meng, X.; Nakamura, T.; Okazaki, T.; Inoue, H.; Takahashi, A.; Miyamoto, S.; Sakaguchi, G.; Eto, M.; Naito, S.; Takeda, M.; Yanagi, Y.; Tani, K. Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Mol. Ther., 2010, 18 (3), 544-551.
68. Studebaker, A. W.; Kreofsky, C. R.; Pierson, C. R.; Russell, S. J.; Galanis, E.; Raffel, C. Treatment of medulloblastoma with a modified measles virus. Neuro. Oncol., 2010, 12(10),1034-1042.
69. Tan, E.; Gouvas, N.; Nicholls, R. J.; Ziprin, P.; Xynos, E.; Tekkis, P. P. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg. Oncol., 2009, 18 (1), 15-24.
70. Dingli, D.; Bergert, E. R.; Bajzer, Z.; O'Connor M.K.; Russell, S. J.; Morris, J. C. Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochem. Biophys. Res. Commun., 2004, 325 (1), 157-166.
71. Dingli, D.; Russell, S. J.; Morris, J. C3rd., In vivo imaging and tumor therapy with the sodium iodide symporter. J. Cell Biochem., 2003, 90 (6), 1079-1086.
72. Iankov, I. D.; Hillestad, M. L.; Dietz, A. B.; Russell, S. J.; Galanis, E. Converting tumor-specific markers into reporters of oncolytic virus infection. Mol. Ther., 2009, 17 (8), 1395-1403.
73. Heinzerling, L.; Kunzi, V.; Oberholzer, P. A.; Kundig, T.; Naim, H.; Dummer, R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon- resistant tumor cells. Blood, 2005, 106 (7), 2287-2294.
74. Galanis, E.; Hartmann, L. C.; Cliby, W. A.; Long, H. J.; Peethambaram, P. P.; Barrette, B. A.; Kaur, J. S.; Haluska, P. J. Jr.; Aderca, I.; Zollman, P. J.; Sloan, J. A.; Keeney, G.; Atherton, P. J.; Podratz, K. C.; Dowdy, S. C.; Stanhope, C. R.; Wilson, T. O.; Federspiel, M. J.; Peng, K. W.; Russell, S. J. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res., 2010, 70 (3), 875-882.
75. Therasse, P.; Arbuck, S. G.; Eisenhauer, E. A.; Wanders, J.; Kaplan, R. S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A. T.; Christian, M. C.; Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst., 2000, 92 (3), 205-216.
76. Markman, M.; Webster, K.; Zanotti, K.; Peterson, G.; Kulp, B.; Belinson, J. Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol. Oncol., 2004, 93 (3), 699-701.
77. Stief, A. E.; McCart, J. A. Oncolytic virotherapy for multiple myeloma. Expert Opin. Biol. Ther., 2008, 8 (4), 463-473.
78. Ong, H. T.; Trejo, T. R.; Pham, L. D.; Oberg, A. L.; Russell, S. J.; Peng, K. W. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol. Ther., 2009, 17 (6), 1012-1021.
79. Hummel, H. D.; Kuntz, G.; Russell, S. J.; Nakamura, T.; Greiner, A.; Einsele, H.; Topp, M. S. Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells. J. Gen. Virol., 2009, 90 (Pt 3), 693-701.
80. Nakamura, T.; Peng, K. W.; Vongpunsawad, S.; Harvey, M.; Mizuguchi, H.; Hayakawa, T.; Cattaneo, R.; Russell, S. J. Antibodytargeted cell fusion. Nat. Biotechnol., 2004, 22 (3), 331-336.
81. Schneider, U.; Bullough, F.; Vongpunsawad, S.; Russell, S. J.; Cattaneo, R. Recombinant measles viruses efficiently entering cells through targeted receptors. J. Virol., 2000, 74 (21), 9928-9936.
82. Hammond, A. L.; Plemper, R. K.; Zhang, J.; Schneider, U.; Russell, S. J.; Cattaneo, R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J. Virol., 2001, 75 (5), 2087-2096.
83. Peng, K. W.; Holler, P. D.; Orr, B. A.; Kranz, D. M.; Russell, S. J. Targeting virus entry and membrane fusion through specific pep tide/MHC complexes using a high-affinity T-cell receptor. Gene. Ther., 2004, 11 (15), 1234-1239.
84. Maisner, A.; Mrkic, B.; Herrler, G.; Moll, M.; Billeter, M. A.; Cattaneo, R.; Klenk, H. D. Recombinant measles virus requiring an exogenous protease for activation of infectivity. J. Gen. Virol., 2000, 81 (Pt 2), 441-449.
85. Ordman, C. W.; Jennings, C. G.; Janeway, C. A. Chemical, Clinical, and immunological studies on the products of human plasma fractionation. Xii. The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prevention and attenuation of measles. J. Clin. Invest., 1944, 23 (4), 541-549.
86. Zingher, A.; Mortimer, P. Convalescent whole blood, plasma and serum in the prophylaxis of measles: JAMA, 12 April, 1926; 1180-1187. Rev. Med. Virol., 2005, 15 (6), 407-418; discussion 418-21.
87. Ong, H. T.; Hasegawa, K.; Dietz, A. B.; Russell, S. J.; Peng, K. W. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene. Ther., 2007, 14 (4), 324-333.
88. Peng, K. W.; Dogan, A.; Vrana, J.; Liu, C.; Ong, H. T.; Kumar, S.; Dispenzieri, A.; Dietz, A. B.; Russell, S. J. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am. J. Hematol., 2009, 84 (7), 401-407.
89. Mader, E. K.; Maeyama, Y.; Lin, Y.; Butler, G. W.; Russell, H. M.; Galanis, E.; Russell, S. J.; Dietz, A. B.; Peng, K. W. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin. Cancer Res., 2009, 15 (23), 7246-7255.
90. Liu, C.; Russell, S. J.; Peng, K. W. Systemic therapy of disseminated myeloma in passively immunized mice using measles virusinfected cell carriers. Mol. Ther., 2010, 18(6),1155-1164.
91. Wei, J.; Wahl, J.; Nakamura, T.; Stiller, D.; Mertens, T.; Debatin, K. M.; Beltinger, C. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas. Gene Ther., 2007, 14 (22), 1573-1586.
92. Haralambieva, I.; Iankov, I.; Hasegawa, K.; Harvey, M.; Russell, S. J.; Peng, K. W. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol. Ther., 2007, 15 (3), 588-597.
93. Shaffer, J. A.; Bellini, W. J.; Rota, P. A. The C protein of measles virus inhibits the type I interferon response. Virology, 2003, 315 (2), 389-397.
94. Takeuchi, K.; Kadota, S. I.; Takeda, M.; Miyajima, N.; Nagata, K. Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett., 2003, 545 (2-3), 177-182.
95. Devaux, P.; von Messling, V.; Songsungthong, W.; Springfeld, C.; Cattaneo, R. Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology, 2007, 360 (1), 72-83.
96. tenOever, B. R.; Servant, M. J.; Grandvaux, N.; Lin, R.; Hiscott, J. Recognition of the measles virus nucleocapsid as a mechanism of IRF-3 activation. J. Virol., 2002, 76 (8), 3659-3669.
97. Hwang, M.; Moretti, L.; Lu, B. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr. Med. Chem., 2009, 16 (24), 3081-3092.
98. Bracarda, S.; Eggermont, A. M.; Samuelsson, J. Redefining the role of interferon in the treatment of malignant diseases. Eur. J. Cancer, 2010, 46 (2), 284-297.
99. Dingli, D.; Cascino, M. D.; Josic, K.; Russell, S. J.; Bajzer, Z. Mathematical modeling of cancer radiovirotherapy. Math Biosci., 2006, 199 (1), 55-78.
100. Bajzer, Z.; Carr, T.; Josic, K.; Russell, S. J.; Dingli, D. Modeling of cancer virotherapy with recombinant measles viruses. J. Theor. Biol., 2008, 252 (1), 109-122.
101. Dingli, D.; Offord, C.; Myers, R.; Peng, K. W.; Carr, T. W.; Josic, K.; Russell, S. J.; Bajzer, Z. Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. Cancer Gene. Ther., 2009, 16 (12), 873-882.
102. Biesecker, M.; Kimn, J. H.; Lu, H.; Dingli, D.; Bajzer, Z. Optimization of virotherapy for cancer. Bull. Math Biol., 2010, 72 (2), 469-489.
103. Duprex, W. P.; McQuaid, S.; Hangartner, L.; Billeter, M. A.; Rima, B. K. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J. Virol., 1999, 73 (11), 9568-9575.